Shucai Zhang

Shucai Zhang

Auto-generated profile, based on publicly available information

Shucai Zhang

Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2020 in ISIJ International
Verified
Journal Article
Open access
PDF file
WJWeichao Jiao
Weichao Jiao
HLHuabing Li
Huabing Li
Hao FengHao Feng
Hao Feng
ZJZhouhua Jiang
Zhouhua Jiang
JDJing Dai
Jing Dai
Wei WuWei Wu
Wei Wu
This study systematically investigated the influence of high nitrogen (N) addition (0.205 wt.%) on microstructure and mechanical properties of as-cast M42 high speed steel. The results demonstrate that the conventional and high-nitrogen M42 cast ingots are mainly composed of martensite, retained austenite and various precipitates (M2C, M6C as well as MC in M42 cast ingot or M(C, N) in M42N cast ingot). The addition of N could increase the retained austenite content, trigger the transformation of MC to M(C, N), favor the formation of M2C at the expense of M6C, and improve the distribution uniformity of M6C at the macroscopic scale. Moreover, the addition of N could lead to the reduction of the secondary dendrite arm spacing as well as the decrease of the thickness and area fraction of eutectic carbides, and improve the distribution uniformity of eutectic carbides at the microscopic scale. The M(C, N) particles form directly from the liquid phase prior to the formation of primary austenite, which could act as the heterogeneous nuclei of primary austenite and thus promote the refinement of the as-cast microstructure. The addition of N slightly decreases the macro-hardness and ultimate compression strength of the cast ingot but increases its ductility, which could be ascribed to the increase of retained austenite content and the reduction in the amount of eutectic carbides. Therefore, high N addition can significantly improve the as-cast microstructure of M42 high speed steel, which is promising for the further enhancement of the mechanical property and service life of the final product.

1 September 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
XTXiaonan Tang
Xiaonan Tang
JMJing Mu
Jing Mu
LMLi Ma
Li Ma
QTQifan Tan
Qifan Tan
JWJinghui Wang
Jinghui Wang
SZShucai Zhang
Shucai Zhang
AZD9291 (osimertinib) is the third-generation EGFR-TKI treat for EGFR mutated NSCLC patients. Despite its encouraging efficacy in clinical, acquired resistance is still inevitable. The mechanism of drug resistance needs to be further explored. In a previous study, we established an AZD9291-resistant cell strain named HCC827/AZDR. We found that insulin-like growth factor binding protein 7 (IGFBP7) expression was markedly increased in HCC827/AZDR cells and AZD9291-resistant patients by RNA sequencing and immunohistochemical analysis, respectively. Reduced IGFBP7 in HCC827/AZDR cells by si-RNA interference recovered the sensitivity to AZD9291 partially and increased AZD9291-induced cell apoptosis. Enhancing IGFBP7 expression in EGFR-mutated non-small cell lung cancer (NSCLC) cells using lentiviruses infection reduced their sensitivity to AZD9291. This study is the first to discover that high IGFBP7 expression could occur following treatment with AZD9291. This might be one of the mechanisms underlying AZD9291 resistance and a potential therapeutic target following AZD9291 resistance.

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FTFenlai Tan
Fenlai Tan
AGAiqin Gu
Aiqin Gu
YZYiping Zhang
Yiping Zhang
SJShun Chang Jiao
Shun Chang Jiao
CWChang-Li Wang
Chang-Li Wang
YSYan Sun
Yan Sun
E19161 Background: The phase III ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS), based on which icotinib was approved by State Food and Drug Administration of China. We conducted a safety-monitoring study to assess the safety and efficacy of icotinib in a broad range of patients with advanced non-small-cell lung cancer (NSCLC) across China. Methods: This study was a single-arm, open-label, multi-center trial in advanced NSCLC patients who were suitable for treatment with oral icotinib 125 mg three times daily. Endpoints included safety, objective response rate (ORR) and disease control rate (DCR), were investigated overall and in subgroups. EGFR mutation analysis was performed retrospectively. Results: Between August, 2011 and August, 2012, 6,087 advanced NSCLC patients were registered with a median age of 63 years (range: 21-95 years), and 5,549 patients were evaluable for safety and tumor response. Baseline characteristics (%) were: male/female 50.8/49.2; non-smoker/ex- or current-smoker/no data 67.2/32.7/0.1; adenocarcinoma/non-adenocarcinoma/other 78.6/15.4/6.0; stage IIIB/IV/other 7.4/90.2/2.4; and 1,571(28.3%) patients were ≥ 70 years of age. The overall incidence of drug-related adverse events (AEs) of any grade was 31.5%, in which the most common drug-related AEs including rash (17.4%) and diarrhea (8.5%), and 3 patients experienced with interstitial lung disease (ILD) associated with icotinib. ORR and DCR were 30.0% and 80.6%, respectively. The safety in the elder patients (age ≥70, n=1,571) were similar to that in the overall population, the incidence of drug-related AEs of any grade was 30.6%, most of which were grade I or II. Among 989 patients who undertook EGFR mutation detection, 738 (74.6%) patients were mutation-positive with an ORR of 49.2% and a DCR of 92.3%. Moreover, in 251 (25.4%) wild type patients, the ORR and DCR were 17.8% and 75.7%, respectively. Conclusions: The data from over 6,000 patients was consistent with the results of the ICOGEN study. Icotinib demonstrated efficacy and a favorable toxicity profile in the routine clinical setting.

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SRShengxiang Ren
Shengxiang Ren
SZShucai Zhang
Shucai Zhang
ZMZhiyong Ma
Zhiyong Ma
HCHourong Cai
Hourong Cai
XXXiaohong Xu
Xiaohong Xu
CZCaicun Zhou
Caicun Zhou
E22143 Background: Autoantibodies is an attractive diagnostic approach for early detection of malignant tumors. Our previous studies found a panel of 7 TAAs(p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5) was associated with lung cancer. We performed this large-scale, multi-center clinical trial to validate their ability to aid early diagnosis of lung cancer in Chinese population. Methods: The 7 TAAs were selected from 43 candidate TAAs from our previous studies, which were detected by ELISA in 1915 participants from 5 clinical centers in China. These samples including lung cancer (n = 818), benign lung diseases (n = 386), healthy volunteers (n = 415) and interference group (n = 296). The sensitivity and specificity from 7 TAAs and the traditional cancer biomarkers CEA, NSE and CYFRA21-1 were compared. Results: The sensitivity and specificity of autoantibody assay were 61% and 90% respectively, which were similar in different subgroups such as age, gender, smoker status and histological type. As for the ...

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YSYuan-kai Shi
Yuan-kai Shi
XHXiaohong Han
Xiaohong Han
LZLi Zhang
Li Zhang
LDLieming Ding
Lieming Ding
NDNicholas Dupuis
Nicholas Dupuis
YSYan Sun
Yan Sun
E20655 Background: ICOGEN was a randomized Phase III clinical trial comparing two EGFR tyrosine kinase inhibitors (TKI), icotinib (I) and gefitinib (G), in EGFR gene mutation status unknown non-small-cell lung cancer (NSCLC) patients previously treated with platinum doublet chemotherapy. Plasma samples from study patients were retrospectively analyzed with a commercially-available blood-based proteomic test which has been shown to have prognostic and predictive properties in NSCLC. This study represents an updated analysis of ICOGEN to evaluate the ability of the test to predict outcome based on therapeutic regimen. Methods: Available pre-treatment plasma samples from ICOGEN were retrospectively analyzed with the proteomic test which classifies subjects as Good or Poor. Progression free survival (PFS ) and over-all survival (OS) were analyzed within treatment (TX) arms and test classification. Results: 352 subjects were evaluated, with 277(78.7%) classified as Good and 75(21.3%) classified as Poor. Among all patients evaluated with the proteomic test, the median PFS was 4.9 mo. and 2.3 mo. (HR [95% CI] 0.61 [0.46 – 0.81]; p = 0.0004) and median OS was 16.6 mo. and 5.5 mo. (HR [95% CI] 0.39 [0.29 – 0.50]; p < 0.0001) for the Good and Poor sub-groups, respectively. Association between test result and PFS was significant in patients treated with I (6.0 mo vs. 1.9 mo, HR = 0.43, p < 0.0001), but not significant in patients treated with G (3.7 mo vs. 2.5 mo, HR = 0.85, p = 0.429). Further evaluation demonstrated that the proteomic test predicted differential therapeutic benefit between icotinib and gefitinib for PFS (pint = 0.036). In OS, a significant association between test result and outcome was shown in both the I (16.3 mo vs. 4.0 mo, HR [95% CI] 0.27[0.19-0.39]; p < 0.0001) and G (16.6 mo vs. 7.0 mo, HR [95% CI] 0.51[0.35-0.76; p = 0.0008) arms, which trended towards prediction of differential therapeutic benefit between icotinib and gefitinib for OS (pint = 0.086). Conclusions: For ICOGEN’s primary study endpoint, the proteomic test was predictive of differential therapeutic benefit between icotinib and gefitinib in EGFR mutations status unknown NSCLC patients.